Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

Inclusion Criteria: * The time between other investigational agents and enrollment on this study is at least 30 days * Pathologically confirmed adenocarcinoma of the pancreas * Patients have localized or locally advanced disease with no evidence of distant metastases * The maximum dimension of the tumor must be =\< 8 cm * Karnofsky Performance Status of 60% or better * Patients with biliary or gastroduodenal obstruction must have drainage or surgical bypass prior to starting chemoradiation * Patients who received chemotherapy \> 5 years ago for malignancies other than pancreatic cancer are eligible, provided that chemotherapy was completed \> 5 years ago and that there is no evidence of the second malignancy at the time of study entry * Patients who received radiation therapy \> 5 years ago for malignancies other than pancreatic cancer and whose radiation therapy field is not overlapping with the 20% isodose line of current radiation field are eligible, provided that radiation therapy was completed \> 5 years ago and that there is no evidence of the second malignancy at the time of study entry * All malignant disease must be able to be encompassed within a single irradiation field * All patients must have radiographically assessable disease * Patients must have a absolute granulocyte count (AGC) greater than or equal to 1500/uL and platelet count greater than or equal to 100,000/uL * Patients must have a serum creatinine less than or equal to 2 mg/dL and total bilirubin less…